This application supports the participation of the University of Chicago in Cancer and Leukemia Group B (CALGB) trials, including scientific and regulatory activities. The CALGB develops and performs clinical trials, primarily large scale clinical trials, to advance the treatment of cancer patients. The University of Chicago is a leading member of CALGB, supplying scientific and administrative leadership including the Group Chair (Dr Schilsky), Committee Chairs (Drs Ratain, Vokes, and Larson), and Study Chairs. Preliminary studies performed at the University of Chicago are taken to CALGB for large scale testing. Laboratories at the University of Chicago perform correlative studies that support CALGB trials. University of Chicago senior faculty mentor junior faculty and fellows in cooperative group participation, with large meeting attendance and eight CALGB Foundation grants awarded to University of Chicago fellows and junior faculty during the past granting period. In addition, The University of Chicago and its eight affiliate institutions are consistently among the top five accruers to CALGB studies with broad participation across all tumor types and substantial minority accrual.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA041287-28
Application #
8464528
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1986-09-30
Project End
2014-02-28
Budget Start
2013-04-01
Budget End
2014-02-28
Support Year
28
Fiscal Year
2013
Total Cost
$237,055
Indirect Cost
$85,096
Name
University of Chicago
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Van Blarigan, Erin L; Fuchs, Charles S; Niedzwiecki, Donna et al. (2018) Marine ?-3 Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance). Cancer Epidemiol Biomarkers Prev 27:438-445
D'Angelo, Sandra P; Mahoney, Michelle R; Van Tine, Brian A et al. (2018) Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol 19:416-426
Innocenti, Federico; Jiang, Chen; Sibley, Alexander B et al. (2018) Genetic variation determines VEGF-A plasma levels in cancer patients. Sci Rep 8:16332
Li, Megan; Mulkey, Flora; Jiang, Chen et al. (2018) Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res 24:4734-4744
Parsons, J Kellogg; Pierce, John P; Mohler, James et al. (2018) Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer. BJU Int 121:534-539
Eisfeld, Ann-Kathrin; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies. Leukemia 32:1338-1348
Stone, Richard M; Mandrekar, Sumithra J; Sanford, Ben L et al. (2017) Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med 377:454-464
Mehrotra, Shailly; Sharma, Manish R; Gray, Elizabeth et al. (2017) Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance). AAPS J 19:1411-1423
Edelman, Martin J; Wang, Xiaofei; Hodgson, Lydia et al. (2017) Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance). J Clin Oncol 35:2184-2192
Campbell, Jeffrey I; Yau, Christina; Krass, Polina et al. (2017) Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat 165:181-191

Showing the most recent 10 out of 224 publications